Disc Medicine (IRON) to Release Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.08. On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Stock Up 0.1 %

Shares of NASDAQ IRON opened at $53.93 on Thursday. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $68.86. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -13.55 and a beta of 0.73. The business has a fifty day simple moving average of $56.62 and a 200-day simple moving average of $55.94.

Insider Activity

In other news, CEO John D. Quisel sold 19,820 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the transaction, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,550,184.10. This represents a 21.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mona Ashiya sold 83,182 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90. Following the transaction, the director now directly owns 194,209 shares in the company, valued at approximately $10,574,680.05. This represents a 29.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 359,408 shares of company stock valued at $20,027,286. Insiders own 4.24% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of several analyst reports. TD Cowen initiated coverage on Disc Medicine in a report on Thursday, February 27th. They set a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank upped their price target on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Finally, Stifel Nicolaus upped their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $89.10.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.